Sunny day on the Stock Exchange for the title Diasorin, which at the beginning of the afternoon gained 5,8%, to 135,25 euros, posting the best increase on the Ftse Mib. The publication of the 2021 accounts triggered the wave of purchases.
Diasorin, accounts 2021
The pharmaceutical group, also thanks to the acquisition of Luminex, closed the last balance sheet with a net profit up by 25,1%, to 310,7 million.
Revenues, on the other hand, increased by 40,4%, to 1,23 billion. This result, the group specified, "is slightly higher than the guidance, which envisaged growth of 40% at constant exchange rates".
The dividend
On the basis of these numbers, the board of directors will therefore propose the distribution of an ordinary dividend of 1,05 euro per share, equal to a total of 57,49 million.
The 2022 guidance
As regards the 2022 targets, DiaSorin expects revenues substantially in line with those recorded in 2021 (approximately -2%), of which those relating to Covid-19 products are down to around 150 million and those ex-Covid are up by about 24%. The EBITDA margin is expected to be around 35%.
As for the geopolitical situation, DiaSorin does not foresee negative impacts from the war between Ukraine and Russia, as it is not "significantly exposed in these areas".
The judgments of the analysts
The 2021 results are "better than expected", while the 2022 guidance is "confirmed", underline the analysts of Equity, who raised the recommendation on the stock to "buy", with a target price of 158 euros.
Promotion also from Banca Akros, which raised the judgment to "buy" from "accumulated", with a target of 172 euros.
For analysts of Intesa Sanpaolo, “the results are better than expected mainly thanks to the good performance of Luminex in the last quarter of the year and to slightly higher than expected sales related to Covid, which had a positive impact on operating profitability”.
